entertainment -WSS

entertainment

author：explore 2025-09-27 23:32:56 - browse：347

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： South Korea throws huge K

WSS

HCA sued by state AG for quality issues at Mission Health

Keeping primary care docs in field isn't impossible, says AAFP CEO

Editas, Vertex strike deal on CRISPR

Friends ask where James Watson's attitudes about race came from

What to know about Virgin Galactic's 1st mission taking paying customers to space

Virtual care provider acquires bankrupt Pear's prescription apps

entertainment

entertainment

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

A biotech analyst on neuroscience, placebo effect, not over

Trump demands the U.S. pay no more for drugs than other countries … again

How to use technology to prevent future drug shortages

Supreme Court strikes down use of affirmative action

In Spain, a hospital brews its own CAR

Novavax promises a turnaround & Lilly roils the obesity market

Anavex keeps shifting the goalposts in its clinical trials

Supreme Court strikes down use of affirmative action

In same hospitals, Black patients receive fewer opioids than white patients

explore

Drastic changes should bring profitability, startup health insurers say

A biotech analyst on neuroscience, placebo effect, not over

A biotech analyst on neuroscience, placebo effect, not over

Hospitals owned by private equity see complications spike 25%

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

NIH trials fail to test meaningful long Covid therapies, experts say

focus

entertainment

focus

leisure time